Citations

Clear

2303 citation(s) found for "Yu, Edward".

Using Protein Microarray as a Diagnostic Assay for Non–Small Cell Lung Cancer
Zhong, Li , Hidalgo, Giovanna E., Stromberg, Arnold J. , Khattar, Nada H., Jett, James R., Hirschowitz, Edward A.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 18, 2005 | Volume: 172 | Issue: 10 | Pages: 1308-1314

10.1164/rccm.200505-830oc | PMID 16109979 Get It

Abstract Rationale Phenotypic and genotypic heterogeneity of lung cancer likely precludes the identification of a single predictive marker and suggests the importance of identifying and measuring multiple markers. Objectives We describe the use of a fluorescent protein microarray to identify and measure multiple non–small cell lung cancer–associated antibodies and show how simultaneous measurements can be combined into a single diagnostic assay. Methods T7 phage cDNA libraries of non–small cell lung cancer were first biopanned with plasma samples from normal subjects and patients with non–small cell lung cancer to enrich the component of tumor-associated proteins, and then applied to microarray slides. Two hundred twelve immunogenic phage-expressed proteins were identified from roughly 4,000 clones, using high-throughput screening with patient plasmas and assayed with 40 cancer and 41 normal plasma samples. Twenty patient and 21 normal plasma samples were randomly chosen and used for statistical determination of the predictive value of each putative marker. Statistical analysis identified antibody reactivity to seven unique phage-expressed proteins that were significantly different (p < 0.01) between patient and normal groups. The remaining 20 patient and 20 normal plasma samples were used as an independent test of the predictive ability of the selected markers. Main Results Measurements of the 5 most predictive phage proteins were combined in a logistic regression model that achieved 90% sensitivity and 95% specificity in prediction of patient samples, whereas leave-one-out statistical analysis achieved 88.9% diagnostic accuracy among all 81 samples. Conclusion Our data indicate that antibody profiling is a promising approach that could achieve high diagnostic accuracy for non–small cell lung cancer.
Volume-Outcome Relationships for Percutaneous Coronary Interventions in the Stent Era
Wu, Chuntao , Walford, Gary, King, Spencer B., Holmes, David R. , Ambrose, John A. , Sharma, Samin, Katz, Stanley, Clark, Luther T. , Jones, Robert H., Hannan, Edward L. , Sharma, Samin

Mayo Clinic

Circulation | August 15, 2005 | Volume: 112 | Issue: 8 | Pages: 1171-1179

10.1161/circulationaha.104.528455 | PMID 16103238 Get It

Background— Most studies that are the basis of recommended volume thresholds for percutaneous coronary interventions (PCIs) predate the routine use of stent placement. Methods and Results— Data from New York’s Percutaneous Coronary Interventions Reporting System in 1998 to 2000 (n=107 713) were used to examine the impact of annual hospital volume and annual operator volume on in-hospital mortality, same-day coronary artery bypass graft (CABG) surgery, and same-stay CABG surgery after adjustment for differences in patients’ severity of illness. For a hospital-volume threshold of 400, the odds ratios for low-volume hospitals versus high-volume hospitals were 1.98 (95% CI, 1.17, 3.35) for in-hospital mortality, 2.07 (95% CI, 1.36, 3.15) for same-day CABG surgery, and 1.51 (95% CI, 1.03, 2.21) for same-stay CABG surgery. For an operator-volume threshold of 75, the odds ratios for low-volume versus high-volume operators were 1.65 (95% CI, 1.05, 2.60) for same-day CABG surgery and 1.55 (95% CI, 1.10, 2.18) for same-stay CABG surgery. Operator volume was not significantly associated with mortality. Also, for hospital volumes below 400 and operator volumes below 75, the respective odds of mortality, same-day CABG surgery, and same-stay CABG surgery were 5.92, 4.02, and 3.92 times the odds for hospital volumes of 400 or higher and operator volumes of 75 or higher. Conclusions— Higher-volume operators and hospitals continue to experience lower risk-adjusted PCI outcome rates.
Unrelated Donor Marrow Transplantation for B-Cell Chronic Lymphocytic Leukemia After Using Myeloablative Conditioning: Results From the Center for International Blood and Marrow Transplant Research
Pavletic, Steven Z. , Khouri, Issa F. , Haagenson, Michael , King, Roberta, Bierman, Philip J., Bishop, Michael R. , Carston, Michael J., Molina, Arturo , Copelan, Edward A. , Ringdén, Olle , Ballen, Karen K. , Weisdorf, Daniel J. , Montserrat, Emili , Anasetti, Claudio , Bishop, Michael Russell , Giralt, Sergio , Roy, Vivek , Adkins, Douglas R. , McCarthy, Philip L. , Ringden, Olov , Weisdorf, Dan

Mayo Clinic

Journal of Clinical Oncology | July 26, 2005 | Volume: 23 | Issue: 24 | Pages: 5788-5794

10.1200/jco.2005.03.962 | PMID 16043827 Get It

Purpose To determine the role of myeloablative conditioning and unrelated donor (URD) bone marrow transplantation in the treatment of patients with advanced B-cell chronic lymphocytic leukemia (CLL). Patients and Methods A total of 38 CLL patients received a matched URD transplant using bone marrow procured by the National Marrow Donor Program. The median age was 45 years (range, 26 to 57 years), the median time from diagnosis was 51 months, and the median number of prior chemotherapy regimens was three. Fifty-five percent of patients were chemotherapy refractory and 89% had received fludarabine. Conditioning included total-body irradiation in 92% of patients. Graft-versus-host disease (GVHD) prophylaxis consisted of methotrexate with cyclosporine or tacrolimus for 82% of patients. Results Twenty-one patients (58%) achieved complete response and six (17%) achieved partial response. Incidences of grades 2 to 4 acute GVHD were 45% at 100 days and incidences of chronic GVHD were 85% at 5 years. Eleven patients are alive and disease free at a median of 6 years (range, 3.0 to 9.0 years). Five-year overall survival, failure-free survival, disease progression rates, and treatment-related mortality (TRM) were 33%, 30%, 32%, and 38% respectively. Conclusion These data demonstrate that lasting remissions can be achieved after URD transplantation in patients with advanced CLL. High TRM suggest that myeloablative conditioning and HLA-mismatched donors should be avoided in future protocols, and it is mandatory to investigate transplant strategies with a lower morbidity and mortality, including the use of nonmyeloablative regimens.
Preserving Olfactory Function in Anterior Craniofacial Surgery through Cribriform Plate Osteotomy Applied in Selected Patients
Feiz‐Erfan, Iman , Han, Patrick P., Spetzler, Robert F., Horn, Eric M., Klopfenstein, Jeffrey D., Kim, Louis J. , Porter, Randall W., Beals, Stephen P., Lettieri, Salvatore C. , Joganic, Edward F., Kim, Louis J.

Mayo Clinic

Operative Neurosurgery | July 13, 2005 | Volume: 57 | Issue: suppl_1 | Pages: 86-93

10.1227/01.neu.0000163487.94463.4a | PMID 15987573 Get It

AbstractOBJECTIVE:Olfaction is often sacrificed to gain access to the cranial base in anterior craniofacial surgery. We describe the long-term results of olfactory function in patients who underwent anterior craniofacial surgery and a cribriform plate osteotomy to preserve olfaction.METHODS:Between 1992 and 2004, 28 patients underwent 29 cribriform plate osteotomies in an attempt to preserve olfaction during anterior craniofacial surgery performed through modified extended transbasal approaches. Patients' charts and office notes were reviewed retrospectively. Formal olfactory testing was available in 5 patients, but most data were based on patients' subjective reports of olfaction. Olfactory preservation was defined by the subjective ability to detect fumes such as coffee, chocolate, roses, and orange juice regardless of the intensity of the sensation. Follow-up was based on phone calls to patients.RESULTS:Four patients were lost to follow-up and excluded. Therefore, follow-up was available in 24 patients after 25 procedures. On the basis of patients' subjective reports, olfaction was spared in 22 patients after 23 procedures (92%) and was confirmed objectively in the five patients formally tested. After surgery, only two patients were anosmic.CONCLUSION:Olfaction can be preserved in selected patients undergoing anterior craniofacial surgery. At least 1 cm of nasal mucosa should remain attached to the cribriform plate, which can be achieved by including the nasal bone in the osteotomy of the orbital bar. A medial orbital canthopexy is therefore necessary after these procedures.
Randomized Phase III Trial of Cisplatin With or Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study
Long, Harry J., Bundy, Brian N. , Grendys, Edward C., Bénda, J, McMeekin, D. Scott, Sorosky, Joel I., Miller, David S. , Eaton, Lynne, Fiorica, James V., Miller, David S

Mayo Clinic

Journal of Clinical Oncology | May 24, 2005 | Volume: 23 | Issue: 21 | Pages: 4626-4633

10.1200/jco.2005.10.021 | PMID 15911865 Get It

Purpose On the basis of reported activity of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) or topotecan plus cisplatin in advanced cervix cancer, we undertook a randomized trial comparing these combinations versus cisplatin alone, to determine whether survival is improved with either combination compared with cisplatin alone, and to compare toxicities and quality of life (QOL) among the regimens. Patients and Methods Eligible patients were randomly allocated to receive cisplatin 50 mg/m2 every 3 weeks (CPT); cisplatin 50 mg/m2 day 1 plus topotecan 0.75 mg/m2 days 1 to 3 every 3 weeks (CT); or methotrexate 30 mg/m2 days 1, 15, and 22, vinblastine 3 mg/m2 days 2, 15, and 22, doxorubicin 30 mg/m2 day 2, and cisplatin 70 mg/m2 day 2 every 4 weeks (MVAC). Survival was the primary end point; response rate and progression-free survival (PFS) were secondary end points. QOL data are reported separately. Results The MVAC arm was closed by the Data Safety Monitoring Board after four treatment-related deaths occurred among 63 patients, and is not included in this analysis. Two hundred ninety-four patients enrolled onto the remaining regimens: 146 to CPT and 147 to CT. Grade 3 to 4 hematologic toxicity was more common with CT. Patients receiving CT had statistically superior outcomes to those receiving CPT, with median overall survival of 9.4 and 6.5 months (P = .017), median PFS of 4.6 and 2.9 months (P = .014), and response rates of 27% and 13%, respectively. Conclusion This is the first randomized phase III trial to demonstrate a survival advantage for combination chemotherapy over cisplatin alone in advanced cervix cancer.
Invited commentary
Laws, Edward R.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 8 | Issue: 3 | Pages: 386-387

10.1007/bf01655083 Get It

Pituitary apoplexy—An endocrine emergency
Laws, Edward R. , Ebersold, Michael J.

Mayo Clinic

World Journal of Surgery | May 8, 2005 | Volume: 6 | Issue: 6 | Pages: 686-688

10.1007/bf01655359 | PMID 7180002 Get It

AbstractSuccessful therapy for pituitary apoplexy depends on prompt recognition of the clinical syndrome, accurate anatomic evaluation of the lesion with the CT scan, intensive steroid replacement therapy, and effective transphenoidal decompression of the tumor. Successful long‐term management of patients who have suffered pituitary apoplexy requires recognition by the complex interrelationships of the pituitary with adrenal, thyroid, gonadal, pancreatic, and gut physiology. Such patients often require multiple medications for replacement therapy. Surgical treatment is often supplemented with radiation therapy, and prolactin‐ and growth hormone‐secreting adenomas may require long‐term management with bromocriptine. Careful follow‐up evaluations and appropriate post‐surgical therapy enable most of these patients to live normal lives.
Primary CNS Lymphoma of T-Cell Origin: A Descriptive Analysis From the International Primary CNS Lymphoma Collaborative Group
Shenkier, Tamara , Blay, Jean‐Yves , Poortmans, Philip , Thiel, Eckhard, Jahnke, Kristoph, Abrey, Lauren E. , Neuwelt, Edward A. , Tsang, Richard , Batchelor, Tracy T. , Ferreri, Andrés J.M. , O’Brien, Peter, Rubenstein, James L. , O’Neill, Brian Patrick , Harris, Nancy L. , Ponzoni, Maurilio , Connors, Joseph M. , Blay, Jean-Yves

Mayo Clinic

Journal of Clinical Oncology | March 30, 2005 | Volume: 23 | Issue: 10 | Pages: 2233-2239

10.1200/jco.2005.07.109 | PMID 15800313 Get It

Purpose To describe the demographic and tumor related characteristics and outcomes for patients with primary T-cell CNS lymphoma (TPCNSL). Patients and Methods A retrospective series of patients with TPCNSL was compiled from twelve cancer centers in seven countries. Results We identified 45 patients with a median age of 60 years (range, 3 to 84 years). Twenty (44%) had Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Twenty-six (58%) had involvement of a cerebral hemisphere and sixteen (36%) had lesions of deeper sites in the brain. Serum lactate dehydrogenase was elevated in 7 (32%) of 22 patients, and CSF protein was elevated in 19 of 24 patients (79%) with available data. The median disease-specific survival (DSS) was 25 months (95% CI, 11 to 38 months). The 2- and 5-year DSS were 51% (95% CI, 35% to 66%) and 17% (95% CI, 6% to 34%), respectively. Univariate and multivariate analyses were conducted for age (≤ 60 v > 60 years), PS (0 or 1 v 2, 3, or 4), involvement of deep structures of the CNS (no v yes), and methotrexate (MTX) use in the primary treatment (yes v no). Only PS and MTX use were significantly associated with better outcome with hazard ratios of 0.2 (95% CI, 0.1 to 0.4) and 0.4 (95% CI, 0.2 to 0.8), respectively. Conclusion This is the largest series ever assembled of TPCNSL. The presentation and outcome appear similar to that of B cell PCNSL. PS 0 or 1 and administration of MTX are associated with better survival.
In Reply:
Patz, Edward F. , Swensen, Stephen J., Herndon, James E.

Mayo Clinic

Journal of Clinical Oncology | March 30, 2005 | Volume: 23 | Issue: 10 | Pages: 2440-2441

10.1200/jco.2005.05.230 Get It

In Reply:
Patz, Edward F. , Swensen, Stephen J., Herndon, James E.

Mayo Clinic

Journal of Clinical Oncology | March 18, 2005 | Volume: 23 | Issue: 9 | Pages: 2107-2108

10.1200/jco.2005.05.267 Get It